GSK Gets a Partial Thumbs Up for Anemia Drug, Ends Plans for RA Drug

As the FDA’s decision date on GSK’s new drug application (NDA) for daprodustat — its chronic kidney disease anemia drug candidate — approaches, an FDA advisory panel said Wednesday that it favors the drug for kidney patients on dialysis but not for patients who aren’t.
Source: Drug Industry Daily